First in Patient Study for PF-06840003 in Malignant Gliomas

Stopped early · Phase 1

Conditions studied: Oligodendroglioma, Astrocytoma, Malignant Glioma

In brief

This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.

Key facts

Study ID

NCT02764151

Run by

Pfizer

People needed

17

Starts

2016-09-09

Expected to finish

2018-12-26

Last updated by the study team

2020-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of WHO Grade IV glioblastoma or WHO Grade III anaplastic gliomas
• For patients with Grade IV GBM, recurrent disease at the time of the first or second recurrence or progression. For patients with Grade III anaplastic gliomas, recurrent disease at the time of at least a first recurrence but no more than a fourth recurrence or progression
• Karnofsky performance score greater than or equal to 70%
• Adequate bone marrow, kidney and liver function

You may not qualify if…

• History of CNS bleeding within 6 months of registration
• Previous anti-angiogenics or anti-vascular endothelial growth factor within 12 months of registration
• Requires treatment with high dose systemic corticosteroids defined as >2 mg/day
• Radiation therapy within 12 weeks of registration

Where it is running

• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• UCLA Clinical & Translational Research Center — Los Angeles, California, United States
• UCLA Oncology Center — Los Angeles, California, United States
• UCLA School of Medicine — Los Angeles, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States
• Columbia University Medical Center — New York, New York, United States
• Columbia University Medical Center — New York, New York, United States
• CUMC Research Pharmacy — New York, New York, United States
• Columbia Doctors Tarrytown — Tarrytown, New York, United States
• Duke Cancer Center — Durham, North Carolina, United States
• Duke University Medical Center, Duke Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.